| 段宝军,白 俊,张 琰.质谱筛选结直肠癌潜在血清标志物的研究 (撤回稿件）[J].中国肿瘤,2018,27(8):619-625. |
| 质谱筛选结直肠癌潜在血清标志物的研究 (撤回稿件） |
| Study of Mass Spectrometry for Screening Potential Serum Biomarker in Colorectal Cancer Patients |
| 投稿时间：2018-01-18 |
| DOI：10.11735/j.issn.1004-0242.2018.08.A011 |
|
 |
| 中文关键词: 结直肠肿瘤 质谱 血清标志物 |
| 英文关键词:colorectal neoplasms mass spectrometry serum biomarker |
| 基金项目: |
|
| 摘要点击次数: 2053 |
| 全文下载次数: 485 |
| 中文摘要: |
| 摘 要：［目的］ 运用弱阳离子磁珠（MB-WCX）联合基质辅助激光解吸离子飞行时间质谱（MALDI-TOF MS）筛选结直肠癌的血清学标志物。［方法］ 收集健康对照（24名）、结直肠癌患者（24例）的血清标本。弱阳离子磁珠分离血清小分子蛋白，MALDI-TOF MS建立健康对照和结直肠癌患者血清蛋白表达谱。Clinprot Tools 2.0软件分析差异表达峰，液相色谱-电喷雾离子化质谱（LC-ESI-MS/MS）鉴定差异表达蛋白。另收集结直肠癌及健康对照样本，ELISA法（各38例）验证血清差异表达蛋白，免疫组化（各40例）验证组织差异表达蛋白。生物信息学分析差异表达蛋白与结直肠癌临床病理特征之间的关系。［结果］ 共发现67个差异表达峰，10个有显著差异（P<0.000001），在结直肠癌中高表达6个，低表达4个，其中m/z：4793.25及m/z：2663.45的差异表达峰经鉴定分别为组蛋白赖氨酸甲基转移酶（SETD7）和纤维蛋白原α前体亚型1（FGA）。结直肠癌患者血清中SETD7蛋白水平较健康对照升高（P=0.000），结直肠癌较癌旁组织中SETD7阳性细胞增多（P=0.003）。生物信息学分析提示SETD7基因表达在结直肠癌组织中显著上调（P=0.008），且其表达水平与T分期有关（P=0.019）。［结论］ 结直肠癌患者与健康对照者血清质谱差异明显，SETD7有望成为新的结直肠癌血清标志物。 |
| 英文摘要: |
| Abstract：［Purpose］ To screen the serum biomarkers for colorectal cancer. ［Methods］ The serum samples of healthy control(control，n=24) and colorectal cancer(CRC，n=24) were collected. Peptidome of all samples were extracted by magnetic beads based weak cation exchange(MB-WCX) chromatography and detected by matrix assisted laser desorption ionization time of flight mass spectrometry(MALDI-TOF MS). The proteomic profile was analyzed by ClinProtTools software 2.0，and the differentially expressed peptides were identified by liquid chromatography-eletronic spray ionization mass/mass(LC-ESI-MS/MS). ELISA(control，n=38 and CRC，n=38) and immunohistochemi-stry(control，n=40 and CRC，n=40) assay were used to validate the differently expressed peptides in serum and tissue respectively. Bioinformatics were used to analyze the relationship between diffe-rentially expressed peptides and clinicopathology features of CRC. ［Results］ Sixty seven m/z peaks were distinguished between control and CRC groups，and 10 peaks were significantly different(P<0.000001). Compared with control group，6 peaks were up-regulated and 4 peaks were down-regulated in CRC. Two peaks(m/z：4793.25 and m/z：2663.45) were identified as histone-lysine N-methyltransferase(SETD7) and isoform 1 of fibrinogen alpha chain precursor(FGA). Compared with control group，the expression of SETD7 was significantly higher in serum(P=0.000) and tissue(P=0.003) of CRC patients. Bioinformatics showed that SETD7 expression was up-regulated in CRC(P=0.008)，and was significantly related to the T stage(P=0.019). ［Conclusion］ The proteomic profiles of control and CRC groups are significantly different，and SETD7 is expected to be a novel serum biomarker for CRC. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|